Mednax Remains Unlikely Target as Medical Mergers Gain Steam

Despite Blackstone Group's  (BX) purchase of TeamHealth Holdings  (TMH) and the pending merger-of-equals transaction between AmSurg  (AMSG) and Envision Healthcare Holdings  (EVHC) , the fourth major physician services firm continues to look like an unlikely seller in the near term. 

Mednax  (MD) , of Sunrise, Fla., differs from its peers in some ways, including corporate culture, and also has been vocal about its own M&A efforts continuing to fuel growth. With new rules associated with MACRA, or the Medicare Access and CHIP Act, around the corner, the company is also positioned to benefit from what is expected to create growing number of smaller-sized acquisition opportunities, industry pundits say. 

Still, if industry dynamics change as a result of recent consolidation, the likelihood of a sizable deal for Mednax may improve.  

On Monday, TeamHealth, which contracts with physician groups and hospitals in emergency medicine and anesthesia, agreed to be taken private by its previous owner, Blackstone, for an enterprise value of about $6.1 billion. The TeamHealth deal came after AmSurg and Envision in June announced an all-stock deal to create a physician services company with an enterprise value of about $15 billion. AmSurg, meanwhile, had previously abandoned its own brief pursuit of TeamHealth in November.

On the sidelines has been Mednax, which through its subsidiaries offers outsourced physician services across the neonatal, anesthesia and maternal-fetal areas. With a current market cap of about $5.7 billion, the company is more than a two billion dollars larger in size than TeamHealth, which for one thing would imply a much higher takeout price. 

Perhaps more important, Mednax is a physician-founded and -run company, unlike its three peers, which are all led by business-minded managers, explained Stifel Nicolaus' Chad Vanacore. Mednax has been led by CEO Dr. Roger J. Medel, who co-founded the company in 1979. Doctors are simply less willing to take a back seat at their companies.

"Selling to private equity is probably not in their DNA," Vanacore said by phone. "When you think about takeout candidates you can talk about willingness to be taken out and ability to be taken out."

At the same time, there's no strategic rationale or strategic pressure in the immediate term to necessarily do a transformative deal, added Brian Tanquilut of Jefferies. 

"They look at their business and feel like they can do a lot on their own," Jefferies Brian Tanquilut added.

While Mednax' own acquisition efforts have been a bit slower than anticipated this year so far, the company is expected to remain a prolific buyer and is already viewed as the most active buyer in the anesthesia services market, followed by Amsurg's Sheridan. Mednax has made 12 practice acquisitions year to date, in addition to some non-medical practice deals.

If you liked this article you might like

Yes, Blackstone Billionaire CEO Schwarzman Still Whispers Things to Trump

Top 5 Things I Learned After Spending the Day With Billionaire Investors

Blackstone Could See $3 Billion Windfall With Vivint IPO or Sale

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Boeing, Pure Storage, Activision Blizzard: 'Mad Money' Lightning Round